Each year nearly 600,000 people-mostly children under age five and pregnant women in sub-Saharan Africa-die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species-Plasmodium falciparum-has proven notoriously resistant to treatment efforts. But thanks to a novel approach developed by scientists at Albert Einstein College of Medicine of Yeshiva University and described in the Jan. 20 online edition of ACS Chemical Biology, researchers can readily screen thousands of drugs to find those potentially able to kill P. falciparum.
Scientists have known for more than a decade that malaria parasites have an Achilles heel: Like all cells, they require two key building blocks-purines and pyrimidines-to synthesize their DNA and RNA. But malaria parasites can’t synthesize purines on their own. Instead, they must import purines from the host red blood cells that they invade. A parasite protein called PfENT1 transports purines from blood cell into the parasites. So drugs that block PfENT1 could conceivably kill the parasites by depriving them of purines they need-but an experimental approach for identifying PfENT1 inhibitors didn’t exist, until now.
Einstein’s Myles Akabas, MD, PhD, developed a novel yeast-based high-throughput assay for identifying inhibitors of the PfENT1 transporter. Akabas worked with two MSTP students in his lab (I.J. Frame and Roman Deniskin) as well as colleagues at Einstein (Drs. Ian Willis and Robyn Moir) and Columbia University (Drs. Donald Landry and David Fidock). The researchers used their technique to screen 64,560 different compounds. They identified 171 potential antimalarial drugs. Studies of nine of the most potent drugs showed that they kill P. falciparum parasites in laboratory culture.
“We’ve shown that the PfENT1 transporter is a potential drug target for developing novel antimalarial drugs,” says Akabas, senior author of the ACS Chemical Biology paper and a professor of physiology and biophysics, of medicine and in the Dominick P. Purpura Department of Neuroscience at Einstein. “By using our rather simple approach, scientists could create similar high-throughput screens to identify inhibitors for killing other parasites that rely on transporters to import essential nutrients.”
Last month, the National Institutes of Health awarded Akabas and his Columbia University collaborators a five-year, $3.45-million grant (1R01AI116665) to use his high-throughput assay to find and develop antimalarial drugs. Albert Einstein College of Medicine of Yeshiva University has applied for patents to cover this assay.
Source: Albert Einstein College of Medicine of Yeshiva University
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.